Skip to main
VRDN

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics is positioned for success with the FDA approval and successful launch of Lumvoa, a best-in-class treatment for TED, and upcoming catalysts, showcasing its strong pipeline and potential for growth. With a new at-home treatment in development and a strong focus on rare diseases, VRDN has potential to capture a significant portion of the market and generate significant revenue in the near future. Its competitive edge and innovative approach make it a favorable investment option for those looking to invest in the healthcare sector.

Bears say

Viridian Therapeutics is facing several challenges, including minimal revenue in the short term due to payer coverage dynamics, competition from larger companies such as AMGN's Tepezza, and the need for additional capital to complete their pipeline and establish commercial manufacturing capabilities. While the company's early commercial launch metrics for Lumvoa and positive results from their clinical trials are encouraging, it remains to be seen how they will compete in the already crowded TED market. Without significant market share or revenue, the company's future success and financial stability may be uncertain.

Viridian Therapeutics (VRDN) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 11 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.